Sort
16,300 grants matching “fatty liver disease”
Role of estrogen-related receptors in cardiac and skeletal muscle
$300,958Janice M Huss · Beckman Research Institute/City Of Hope · R01 · FY2009 · DK
Hepatic Insulin Resistance Following Hemorrhage
$300,948Joseph Louis Messina · University Of Alabama At Birmingham · R01 · FY2012 · DK
Effects of maternal cortisol on fetal and neonatal growth and metabolism
$300,948Maureen Keller-Wood · University Of Florida · R01 · FY2010 · HD
Hepatic Insulin Resistance Following Hemorrhage
$300,948Joseph Louis Messina · University Of Alabama At Birmingham · R01 · FY2011 · DK
Regulation of Lipogenesis
$300,891Hei Sook Sul · University Of California Berkeley · R01 · FY2011 · DK
Dietary Factors in Colon Cancer Prevention
$300,875Frank Albert Simmen · Univ Of Arkansas For Med Scis · R01 · FY2010 · CA
Effect of Aging on Preadipocyte Differentiation
$300,875James L. Kirkland · Mayo Clinic Rochester · R01 · FY2009 · AG
Cyclin D1/CDK4 Complex in Hepatocyte Proliferation
$300,834Jeffrey H Albrecht · Hennepin Healthcare Research Institute · R01 · FY2009 · DK
CONTROL OF DRUG AND ETHANOL METABOLISM
$300,791University Of Louisville · R01 · FY2003 · AA
Proteomic profiling of NASH: disease mechanisms and novel treatment
$300,742Dennis Petersen · University Of Colorado Denver · R01 · FY2011 · DK
Pathophysiology and Characterisation of NAFLD
$300,493Michael R Charlton · Mayo Clinic Rochester · R01 · FY2007 · DK
Effects of amino acids on regional lipid metabolism
$300,420Elisabet Borsheim · University Of Texas Med Br Galveston · R01 · FY2010 · AG
Collaborative Clinical Research in Nonalcoholic Steatohepatitis
$300,419Naga P. Chalasani · Indiana University Indianapolis · U01 · FY2020 · DK
A Novel Role of the Aryl Hydrocarbon Receptor in Hepatic Steatosis
$300,326Wen Xie · University Of Pittsburgh At Pittsburgh · R01 · FY2013 · DK
Molecular Physiology of Liver Fatty Acid Transporters
$300,080Palo Alto Medical Foundation Res Inst · R01 · FY2004 · DK
Molecular Physiology of Liver Fatty Acid Transporters
$300,080Palo Alto Medical Foundation Res Inst · R01 · FY2005 · DK
Targeting galectin-3 to overcome insulin resistance in type 2 diabetes
$300,000Hafiz Ahmed · Glycomantra, Inc. · R43 · FY2020 · DK
Collaborative Research: High-throughput microliver platform for drug toxicity screening
$300,000Salman R Khetani · University Of Illinois At Chicago · · FY2017 · ENG
Targeting galectin-3 to intervene COVID-19
$300,000Hafiz Ahmed · Glycomantra, Inc. · R43 · FY2022 · AI
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS THE MOST COMMON CAUSE OF LIVER DISEASE IN THE UNITED STATES, AFFECTING APPROXIMATELY 80 MILLION ADULTS. IMPORTANTLY, RISK FACTORS FOR THE DEVELOPMENT OF NAFLD TEND TO INCREASE IN PREVALENCE WITH ADVANCING AGE. THE PATHOGENESIS OF NAFLD HAS BEEN CONSIDERED AS DEVELOPING FROM PREVALENT MULTIPLE PARALLEL FACTORS, INCLUDING GUT-LIVER AXIS, INFLAMMATORY PATHWAYS, AND THE HIGH-FAT WESTERN DIETS. NAFLD DISPLAYS KEY CHARACTERISTICS, SUCH AS INTESTINAL DYSBIOSIS AND GUT PERMEABILITY. IDENTIFICATION OF PREVIOUSLY UNRECOGNIZED MOLECULES CONTRIBUTING TO NAFLD VIA GUT-LIVER AXIS WILL HELP TO UNDERSTAND THE ACTION MECHANISMS FURTHER AND TO DEVELOP EFFICIENT PREVENTION STRATEGIES. GROWING EVIDENCE INDICATES THAT THE ENDOCANNABINOID SYSTEM (ECS) IS INTIMATELY INVOLVED IN THE DEVELOPMENT OF OBESITY AND TYPE 2 DIABETES (T2D), THE EARLIEST METABOLIC DRIVER OF NAFLD, MAINLY BY ACTIVATING THE CANNABINOID 1 RECEPTOR (CB1R) TO TARGET CENTRAL AND PERIPHERAL SITES SUCH AS THE LIVER. THE PREVIOUS STUDIES DISCOVERED THAT L-THEANINE, A NON-PROTEIN WATER-SOLUBLE AMINO ACID CHARACTERISTICALLY FOUND IN TEA PLANTS, CAN BIND TO CB1R AND INHIBIT ITS ACTIVITY. THUS, THE OBJECTIVE OF THIS PROJECT IS TO DETERMINE THE ROLE OF CB1R VIA GUT-LIVER AXIS IN THE TEA BIOACTIVITIES. THE RESULTS OF THIS PROJECT WILL HAVE SIGNIFICANT IMPLICATIONS BY PROVIDING FUNDAMENTAL GUIDELINES AND JUSTIFICATION FOR DEVELOPMENT OF FUTURE PROJECTS EXAMINING THE EFFECTS OF FOOD AND GUT HEALTH ON NAFLD.
$300,000Oklahoma State University · · FY2024 · National Institute of Food and Agriculture
Discerning the influence of maternal obesity, weight gain, and diet on the infant microbiota and programming of NAFLD
$300,000Jacob E Friedman · University Of Colorado Denver · R56 · FY2018 · DK
Soft LXR Agonists for the Treatment of Idiopathic Pulmonary Fibrosis
$300,000Jay Edward Wrobel · Fox Chase Chemical Diversity Center, Inc · R43 · FY2018 · HL
Mesenteric Fat Cryolipolysis to Reverse Insulin Resistance
$300,000Rafi Mazor · B2m Medical, Inc. · R43 · FY2022 · DK
Pregnane X Receptor (PXR) Antagonists for Non-Alcoholic Fatty Liver Disease
$300,000Jay Edward Wrobel · Fox Chase Chemical Diversity Center, Inc · R43 · FY2015 · DK
Evolutionary Advantage of Heterozygous PAI-1 Deficiency in Humans
$300,000Douglas Eugene Vaughan · Northwestern University At Chicago · R56 · FY2022 · AG